Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging

Molecular Imaging and Biology

Volumn 18, Issue 1, 2016, Pages 79-89

  Zhang, Liang ^a   Thurber, Greg M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Exendin; Glucagon like peptide 1 receptor; Type 1 diabetes imaging

Indexed keywords

ALBUMIN; DIMER; EXENDIN 4; FLUORESCENT DYE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MONOMER; BENZENESULFONIC ACID DERIVATIVE; GREEN FLUORESCENT PROTEIN; INDOLE DERIVATIVE; IRDYE 800CW; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOWN REGULATION; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; ELECTROSPRAY MASS SPECTROMETRY; IN VIVO STUDY; KIDNEY; LIVER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; ENDOCYTOSIS; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PROCEDURES;

ANIMALS; BENZENESULFONATES; DOWN-REGULATION; ENDOCYTOSIS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GREEN FLUORESCENT PROTEINS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOLES; MICE, INBRED C57BL; MOLECULAR IMAGING; PEPTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VENOMS;

EID: 84955672165     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0880-2     Document Type: Article

References (82)

1. Reiner T, Kohler RH, Liew CW et al (2010) Near-infrared fluorescent probe for imaging of pancreatic beta cells. Bioconjug Chem 21:1362–1368
2. Bandara N, Zheleznyak A, Cherukuri K, et al. (2015) Evaluation of Cu-64 and Ga-68 radiolabeled glucagon-like peptide-1 receptor agonists as PET tracers for pancreatic beta cell imaging. Mol Imaging Biol
3. Goke B (2010) What are the potential benefits of clinical beta-cell imaging in diabetes mellitus? Curr Pharm Des 16:1547–1549
4. Holmberg D, Ahlgren U (2008) Imaging the pancreas: from ex vivo to non-invasive technology. Diabetologia 51:2148–2154
5. Arifin DR, Bulte JWM (2011) Imaging of pancreatic islet cells. Diabetes Metab Res Rev 27:761–766
6. Ichise M, Harris PE (2010) Imaging of beta-cell mass and function. J Nucl Med 51:1001–1004
7. Boerman OC, Gotthardt M (2012) F-18-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster? Eur J Nucl Med Mol Imaging 39:461–462
8. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS (1986) The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29:267–274
9. Chmelova H, Cohrs CM, Chouinard JA et al (2015) Distinct roles of beta cell mass and function during type 1 diabetes onset and remission. Diabetes 64:2148–2160
10. Saudek F, Brogren CH, Manohar S (2008) Imaging the beta-cell mass: why and how. Rev Diabet Stud 5:6–12
11. Steiner DJ, Kim A, Miller K, Hara M (2010) Pancreatic islet plasticity interspecies comparison of islet architecture and composition. Islets 2:135–145
12. Saisho Y, Butler AE, Manesso E et al (2013) Beta-cell mass and turnover in humans effects of obesity and aging. Diabetes Care 36:111–117
13. Medarova Z, Evgenov NV, Dai G et al (2006) In vivo multimodal imaging of transplanted pancreatic islets. Nat Protoc 1:429–435
14. McCulloch DK, Koerker DJ, Kahn SE et al (1991) Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 40:673–679
15. Brom M, Andraojc K, Oyen WJG et al (2010) Development of radiotracers for the determination of the beta-cell mass in vivo. Curr Pharm Des 16:1561–1567
16. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 50:382–389
17. Gepts W, Lecompte PM (1981) The pancreatic islets in diabetes. Am J Med 70:105–115
18. Sweet IR, Cook DL, Lernmark A et al (2004) Systematic screening of potential beta-cell imaging agents. Biochem Biophys Res Commun 314:976–983
19. Moore A, Bonner-Weir S, Weissleder R (2001) Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes 50:2231–2236
20. Schneider S, Feilen PJ, Schreckenberger M et al (2005) In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp Clin Endocrinol Diabetes 113:388–395
21. Harris PE, Ferrara C, Barba P et al (2008) VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med 86:5–16
22. Souza F, Simpson N, Raffo A et al (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116:1506–1513
23. Virostko J, Henske J, Vinet L et al (2011) Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands. Proc Natl Acad Sci U S A 108:20719–20724
24. Reiner T, Thurber G, Gaglia J et al (2011) Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci U S A 108:12815–12820
25. Di Gialleonardo V, de Vries EF, Di Girolamo M et al (2012) Imaging of beta-cell mass and insulitis in insulin-dependent (type 1) diabetes mellitus. Endocr Rev 33:892–919
26. Basu S, Alavi A (2007) Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging 34:1527–1529
27. Basu S, Zaidi H, Houseni M et al (2007) Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med 37:223–239
28. Chawluk JB, Alavi A, Dann R et al (1987) Positron emission tomography in aging and dementia: effect of cerebral atrophy. J Nucl Med 28:431–437
29. Hickeson M, Yun MJ, Matthies A et al (2002) Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29:1639–1647
30. Srinivas SM, Dhurairaj T, Basu S et al (2009) A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med 23:341–348
31. Tanna NK, Kohn MI, Horwich DN et al (1991) Analysis of brain and cerebrospinal-fluid volumes with MR imaging: impact on PET data correction for atrophy. Part II. Aging and Alzheimer dementia. Radiology 178:123–130
32. Sweet IR, Cook DL, Lernmark A et al (2004) Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 6:652–659
33. Keliher EJ, Reiner T, Thurber GM et al (2012) Efficient 18F-labeling of synthetic exendin-4 analogues for imaging beta cells. ChemistryOpen 1:177–183
34. Brand C, Abdel-Atti D, Zhang Y et al (2014) In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjug Chem 25:1323–1330
35. Eng J, Kleinman WA, Singh L et al (1992) Isolation and characterization of exendin-4, an exendin-3 analog, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402–7405
36. Gotthardt M, Lalyko G, van Eerd-Vismale J et al (2006) A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 137:162–167
37. Goke R, Fehmann HC, Linn T et al (1993) Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650–19655
38. Kolligs F, Fehmann HC, Goke R, Goke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin(9–39) amide. Diabetes 44:16–19
39. Gotthardt M, Fischer M, Naeher I et al (2002) Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 29:597–606
40. Wicki A, Wild D, Storch D et al (2007) [Lys(40)(Ahx-DTPA-In-111)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 13:3696–3705
41. Mikkola K, Yim CB, Fagerholm V et al (2014) 64Cu- and 68Ga-labelled [Nle(14), Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats. Mol Imaging Biol 16:255–263
42. Wild D, Wicki A, Mansi R et al (2010) Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 51:1059–1067
43. Zhang L, Navaratna T, Liao JS, Thurber GM (2015) Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands. Bioconjug Chem 26:329–337
44. Gao HK, Niu G, Yang M et al (2011) PET of insulinoma using F-18-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm 8:1775–1782
45. Virostko J, Jansen ED, Powers AC (2006) Current status of imaging pancreatic islets. Curr Diabetes Rep 6:328–332
46. Kim TH, Jiang HH, Lee S et al (2011) Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconjug Chem 22:625–632
47. Kim TH, Jiang HH, Lim SM et al (2012) Site-specific PEGylated exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects. Bioconjug Chem 23:2214–2220
48. Widmann C, Dolci W, Thorens B (1995) Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J 310(Pt 1):203–214
49. Schmidt MM, Thurber GM, Wittrup KD (2008) Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 57:1879–1890
50. Oliveira S, Cohen R, Walsum MS et al (2012) A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Res 2:50
51. Runge S, Thogersen H, Madsen K et al (2008) Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 283:11340–11347
52. Berezin MY, Guo K, Akers W et al (2011) Rational approach to select small peptide molecular probes labeled with fluorescent cyanine dyes for in vivo optical imaging. Biochemistry 50:2691–2700
53. Thurber GM, Weissleder R (2011) A systems approach for tumor pharmacokinetics. PLoS ONE 6
54. Bhatnagar S, Deschenes E, Liao JS et al (2014) Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors. J Pharm Sci 103:3276–3286
55. Fujita H, Morii T, Fujishima H et al (2014) The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85:579–589
56. Liu WJ, Xie SH, Liu YN et al (2012) Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 340:248–255
57. Pyke C, Heller RS, Kirk RK et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1290
58. Waser B, Blank A, Karamitopoulou E et al (2015) Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas. Mod Pathol 28:391–402
59. Wang QH, Chen K, Liu R et al (2010) Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One 5:9
60. Levy OE, Jodka CM, Ren SS et al (2014) Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. PLoS One 9:e87704
61. Glaesner W, Vick AM, Millican R et al (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 26:287–296
62. Thurber GM, Schmidt MM, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57–61
63. Reynolds F, Kelly KA (2011) Techniques for molecular imaging probe design. Mol Imaging 10:407–419
64. Mattes MJ, Griffiths G, Diril H et al (1994) Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 73:787–793
65. Wild D, Behe M, Wicki A et al (2006) [Lys(40) (Ahx-DTPA-In-111)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47:2025–2033
66. Roed SN, Wismann P, Underwood CR et al (2014) Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Mol Cell Endocrinol 382:938–949
67. Bavec A, Licar A (2009) Functional characterization of N-terminally GFP-tagged GLP-1 receptor. J Biomed Biotechnol
68. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861
69. Vegt E, Melis M, Eek A et al (2011) Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 38:623–632
70. Li ZB, Cai WB, Cao QZ et al (2007) 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 48:1162–1171
71. Cheng Z, Wu Y, Xiong ZM et al (2005) Near-infrared fluorescent RGD peptides for optical imaging of integrin alpha(v)beta 3 expression in living mice. Bioconjug Chem 16:1433–1441
72. Stern LA, Case BA, Hackel BJ (2013) Alternative non-antibody protein scaffolds for molecular imaging of cancer. Curr Opin Chem Eng 2
73. Moore SJ, Gephart MGH, Bergen JM et al (2013) Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma. Proc Natl Acad Sci U S A 110:14598–14603
74. Cilliers C, Liao J, Atangcho L, Thurber GM (2015) Residualization rates of near-infrared dyes for the rational design of molecular imaging agents. Mol Imaging Biol
75. Hahnenkamp A, Alsibai W, Bremer C, Holtke C (2014) Optimizing the bioavailability of small molecular optical imaging probes by conjugation to an albumin affinity tag. J Control Release 186:32–40
76. Pollaro L, Raghunathan S, Morales-Sanfrutos J et al (2015) Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors. Mol Cancer Ther 14:151–161
77. Geng SB, Cheung JK, Narasimhan C et al (2014) Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. J Pharm Sci 103:3356–3363
78. Hotzel I, Theil FP, Bernstein LJ et al (2012) A strategy for risk mitigation of antibodies with fast clearance. MAbs 4:753–760
79. Tolmachev V, Tran TA, Rosik D et al (2012) Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 53:953–960
80. Samkoe KS, Tichauer KM, Gunn JR et al (2014) Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. Cancer Res 74:7465–7474
81. Hampe CS, Wallen AR, Schlosser M et al (2005) Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass. Exp Clin Endocrinol Diabetes 113:381–387
82. Kavishwar A, Moore A (2013) Sphingomyelin patches on pancreatic beta-cells are indicative of insulin secretory capacity. J Histochem Cytochem 61:910–919